Trial Profile
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs DP b99 (Primary)
- Indications Stroke
- Focus Registrational; Therapeutic Use
- Acronyms MASCI
- 14 Feb 2013 New trial record
- 07 Feb 2013 Primary endpoint 'Rankin-scale' has not been met.
- 07 Feb 2013 Results presented at the 38th International Stroke Conference.